Repositioning Proton Pump Inhibitors as Anticancer Drugs by Targeting the Thioesterase Domain of Human Fatty Acid Synthase

Citations Over TimeTop 25% of 2014 papers

Abstract

Fatty acid synthase (FASN), the enzyme responsible for de novo synthesis of free fatty acids, is up-regulated in many cancers. FASN is essential for cancer cell survival and contributes to drug resistance and poor prognosis. However, it is not expressed in most nonlipogenic normal tissues. Thus, FASN is a desirable target for drug discovery. Although different FASN inhibitors have been identified, none has successfully moved into clinical use. In this study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of the thioesterase activity of human FASN. Further investigation showed that PPIs inhibited proliferation and induced apoptosis of cancer cells. Supplementation of palmitate, the end product of FASN catalysis, rescued cancer cells from PPI-induced cell death. These findings provide new evidence for the mechanism by which this FDA-approved class of compounds may be acting on cancer cells.

Related Papers

• → Human fatty acid synthase: Structure and substrate selectivity of the thioesterase domain(2004)197 cited
• → Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat(2007)179 cited
• → Novel antagonists of the thioesterase domain of human fatty acid synthase(2007)27 cited
• → Effect of Modification of the Length and Flexibility of the Acyl Carrier Protein−Thioesterase Interdomain Linker on Functionality of the Animal Fatty Acid Synthase(2005)31 cited
• Selective inhibitors of FAS-TE(2014)